BioWorld

Feb. 3, 2005

View Archived Issues

Nuvelo Stock Offer: $63.75M For Alfimeprase, Other Drugs

Proving its financial mettle even without the hoped-for larger alfimeprase deal with Amgen Inc., Nuvelo Inc. priced an offering of 8.5 million shares at $7.50 each to pull down $63.75 million. (BioWorld Today) Read More

Kyorin Pays $21M For ActivX To Be U.S.-Based Research Center

Read More

Tweaking Receptor Balancing Act To Reverse Autoimmunity

Read More

MEND Act Unveiled As Approach For Better Medicare Buying Power

Read More

FDA Approves Nascobal After Manufacturing Issues Solved

Read More

Other News To Note

Read More

Appointments And Advancements

Read More